Tagged with Novartis,

Turkey Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical industry and the government.   Through its Sandoz division, Novartis has been in Turkey since 1930 Can you introduce the…

Algeria Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies to ensure sustainability within the Algerian market.   You’ve been in Algeria for four years. Can you enlighten our viewers…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK The Top 15 pharmaceutical companies in the UK in the year up to March 2018 according to IQVIA data, ranked by market share. Pfizer leads the way with a whopping 8.2% market share, followed by Novartis with 6% and GSK with 5.3%

Algeria Karim Harchaoui, country manager of Novartis Algeria, explains the rationale behind the recent restructuring of the Algerian affiliate, the evolution of the company’s local manufacturing footprint, and the strategic importance of Algeria to Novartis within the Africa and Middle East region.   Novartis has undergone an extensive restructuring of the…

Cancer Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after receiving European Commission (EC) approval. “It’s fantastic news for children and young people with this form of leukaemia.” Prof Charles Swanton, Cancer Research UK’s Dubbed as the future of cancer therapy, Kymriah, Novartis’ gene-modifying treatment…

Regulatory This week Novartis received approval from the European Commission (EC) for Kymriah, their chimeric antigen receptor T cell (CAR-T) therapy for young people under 25 with cancer of the blood. Leading the way in innovative cancer cures with an unrivalled portfolio of over 20 approved oncology medicines, Novartis is the only company in the…

Pharma What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets virtual objects against the backdrop of the real world—as in Pokemon Go, the augmented reality smartphone craze of 2016—or simply…

Novartis In the latest in a wave of Big Pharma companies retreating from the field of antibiotics, Novartis has decided to drop its antibacterial and antiviral early-stage research programs, laying off 140 staff in the US. This comes at a time when antibiotic-resistant strains of bacteria – so-called ‘superbugs’ – are…

Turkey The top 15 pharma companies in Turkey ranked by sales for 2017. Homegrown champion Ibrahim leads the way with USD 420 million worth of sales and a 5.8 percent market share, followed by global giants Novartis and Pfizer.

UK As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical industry and the patients who rely on it are under serious threat from Brexit” Erik Nordkamp, Pfizer Erik Nordkamp, the…

Portugal Cristina Campos is well known on the Portuguese pharmaceutical circuit, directing the affiliate of market leader, Novartis, and holding a position as vice-president at APIFARMA, the Portuguese Pharmaceutical Association. In her second meeting with PharmaBoardroom, Campos discusses the Portuguese ‘talent machine’, an exciting new portfolio with incredibly strong launches on…